Compound: GANAXOLONE
SMILES: O=C([C@@H]1[C@@]2([C@H]([C@H]3[C@@H]([C@@]4([C@H](C[C@@](O)(C)CC4)CC3)C)CC2)CC1)C)C
InChIKey: PGTVWKLGGCQMBR-FLBATMFCSA-N
Synonyms: GANAXOLONE, 38398-32-2, Ztalmy, CCD 1042, 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one, CCD-1042, ganaxolona, CCD1042, 98WI44OHIQ, DTXSID6046503, DEA NO. 2401, DTXCID4026503, Pregnan-20-one, 3-hydroxy-3-methyl-, (3alpha,5alpha)-, ganaxolonum, RefChem:57127, 1-((1S,2S,5R,7S,10R,11S,14S,15S)-5-hydroxy-2,5,15-trimethyltetracyclo(8.7.0.02,?.011,1?)heptadecan-14-yl)ethan-1-one, 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone, 1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-Hydroxy-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone, C22H36O2, NCGC00165802-02, CAS-38398-32-2, Ganaxolone [USAN], Ganaxolone [USAN:INN], UNII-98WI44OHIQ, Ganaxolone, solid, Pregnan-20-one, 3-hydroxy-3-methyl-, (3a,5a)-; (3a,5a)-3-Hydroxy-3-methylpregnan-20-one; 3a-Hydroxy-3ss-methyl-5a-pregnan-20-one; 5a-Pregnan-20-one, 3a-hydroxy-3-methyl-; CCD 1042; Ganaxolone, Pregnan-20-one, 3-hydroxy-3-methyl-, (3a,5a)-, Ztalmy (TN), GANAXOLONE [MI], GANAXOLONE [INN], Ganaxolone (USAN/INN), 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one, GANAXOLONE [WHO-DD], SCHEMBL144522, (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one, CHEMBL1568698, GTPL11942, CHEBI:177658, PGTVWKLGGCQMBR-FLBATMFCSA-N, HMS3261K19, Tox21_112264, Tox21_500379, BDBM50369240, MFCD09971088, AKOS027327586, Tox21_112264_1, CCG-221683, DB05087, LP00379, SDCCGSBI-0633706.P001, NCGC00165802-03, NCGC00261064-01, NCGC00263545-01, 1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one, AS-35253, FG158986, SY242175, 3?-Hydroxy-3?-methyl-5?-pregnan-20-one, NS00069337, (3?,5?)-3-Hydroxy-3-methylpregnan-20-one, D04300, (3alpha,5alpha)-3-hydroxy-3-methyl-pregnan-20-one, Q3758034, BRD-K28217197-001-01-4, 3.ALPHA.-HYDROXY-3-METHYL-5.ALPHA.-PREGNAN-20-ONE, PREGNAN-20-ONE, 3-HYDROXY-3-METHYL-, (3.ALPHA.,5.ALPHA.)-
Theoretical properties:
molecular_formula: C22H36O2
molecular_weight: 332.5 g/mol
exact_mass: 332.271530387 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 1
heavy_atom_count: 24
topological_polar_surface_area: 37.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 190-198C
solubility: Low aqueous solubility
Descriptions:
pubchem: Ganaxolone is a corticosteroid hormone.
chembl: GANAXOLONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Ganaxolone, sold under the brand name Ztalmy, is a medication used to treat seizures in people with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. Ganaxolone is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator.
The most common side effects of treatment with ganaxolone include somnolence (sleepiness), fever, excessive saliva or drooling, and seasonal allergy.
Ganaxolone was approved for medical use in the United States in March 2022, and in the European Union in July 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.